

Lubica Rauova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8133898/publications.pdf>

Version: 2024-02-01

94
papers

3,324
citations

159585

30
h-index

149698

56
g-index

96
all docs

96
docs citations

96
times ranked

3513
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel role for endoplasmic reticulum protein 46 (ERp46) in platelet function and arterial thrombosis in mice. <i>Blood</i> , 2022, 139, 2050-2065.	1.4	3
2	Signaling Through Fc γ RIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834988.	4.8	26
3	Understanding VITT(ual) reality. <i>Blood</i> , 2021, 138, 285-286.	1.4	2
4	Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. <i>Blood</i> , 2021, 138, 2106-2116.	1.4	23
5	Fc-Modified Kko: A Novel Therapeutic for Heparin-Induced Thrombocytopenia (HIT), Reversing Both the Thrombocytopenia and Thrombosis. <i>Blood</i> , 2021, 138, 581-581.	1.4	1
6	Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications. <i>Blood</i> , 2021, 138, 292-292.	1.4	5
7	Platelet Factor 4 (PF4) Modulates the Prothrombotic Nature of Neutrophil-Extracellular Traps (NETs): Therapeutic Implications of a NET-Stabilization Strategy. <i>Blood</i> , 2021, 138, 2096-2096.	1.4	2
8	In Situ Microscopy Studies of Infused Megakaryocytes: Implications in Thrombopoiesis. <i>Blood</i> , 2021, 138, 4287-4287.	1.4	0
9	The Role of PF4 Antibodies in Pediatric Sars-Cov-2 Infections. <i>Blood</i> , 2021, 138, 1004-1004.	1.4	0
10	Minimal Role for the Alternative Pathway in Complement Activation By HIT Immune Complexes. <i>Blood</i> , 2021, 138, 2076-2076.	1.4	0
11	In systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation. <i>Journal of Autoimmunity</i> , 2020, 107, 102355.	6.5	23
12	CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration. <i>Cellular Signalling</i> , 2020, 66, 109488.	3.6	14
13	Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. <i>Blood</i> , 2020, 135, 1270-1280.	1.4	55
14	Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis. <i>Blood</i> , 2020, 135, 743-754.	1.4	39
15	Platelet Activation in Heparin-Induced Thrombocytopenia is Followed by Platelet Death via Complex Apoptotic and Non-Apoptotic Pathways. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2556.	4.1	7
16	Abnormal clot microstructure formed in blood containing HIT-like antibodies. <i>Thrombosis Research</i> , 2020, 193, 25-30.	1.7	3
17	FcRn augments induction of tissue factor activity by IgG-containing immune complexes. <i>Blood</i> , 2020, 135, 2085-2093.	1.4	19
18	Complement Regulates the Procoagulant Effects of HIT Immune Complexes. <i>Blood</i> , 2020, 136, 11-12.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death. <i>Cell Death Discovery</i> , 2019, 5, 106.	4.7	35
20	Illustrated State of the Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	2.3	11
21	Understanding How Fc-Modification Transforms a Pathogenic Heparin-Induced Thrombocytopenia (HIT)-like Monoclonal Antibody into a Novel Treatment for Sepsis. <i>Blood</i> , 2019, 134, 10-10.	1.4	0
22	Neutrophil accumulation and NET release contribute to thrombosis in HIT. <i>JCI Insight</i> , 2018, 3, .	5.0	115
23	Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway. <i>Blood</i> , 2018, 132, 2431-2440.	1.4	35
24	Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT). <i>Autoimmunity Reviews</i> , 2018, 17, 1046-1052.	5.8	11
25	Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. <i>Blood</i> , 2018, 132, 727-734.	1.4	9
26	Antibody Stabilization of Neutrophil Extracellular Trap-Platelet Factor 4 Complexes Is Therapeutic in a Murine Model of Endotoxemia. <i>Blood</i> , 2018, 132, 271-271.	1.4	0
27	The disulfide isomerase ERp72 supports arterial thrombosis in mice. <i>Blood</i> , 2017, 130, 817-828.	1.4	45
28	Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies. <i>Blood Advances</i> , 2017, 1, 644-651.	5.2	9
29	Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. <i>Journal of Clinical Investigation</i> , 2017, 127, 1090-1098.	8.2	37
30	Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2016, 1, 62-74.	5.2	58
31	Role of monocytes and endothelial cells in heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 806-812.	3.4	15
32	Platelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral Attachment. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 705-717.	1.1	21
33	Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. <i>Blood</i> , 2016, 127, 464-472.	1.4	86
34	The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21). <i>Blood</i> , 2016, 128, 1789-1799.	1.4	45
35	A Special Role for Neutrophil Extracellular Traps (NETs) and Neutrophils in the Prothrombotic Nature of Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2016, 128, 1023-1023.	1.4	1
36	Platelet Release from Infused CD34+-Derived Human Megakaryocytes: Lessons from a Natural-Occurring Platelet Bioreactor. <i>Blood</i> , 2016, 128, 1375-1375.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Apoptosis Might Contribute to the Thrombocytopenia in Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2016, 128, 2545-2545.	1.4	0
38	The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis. <i>Journal of Clinical Investigation</i> , 2015, 125, 4391-4406.	8.2	79
39	Atomic description of the immune complex involved in heparin-induced thrombocytopenia. <i>Nature Communications</i> , 2015, 6, 8277.	12.8	101
40	Characterization of Human and Murine Anti-Protamine/Heparin Antibodies. <i>Blood</i> , 2015, 126, 3461-3461.	1.4	1
41	The Second CGHC Motif of Protein Disulfide Isomerase Mediates Thrombosis. <i>Blood</i> , 2015, 126, 1032-1032.	1.4	0
42	Membrane Remodeling By Pathogenic Antibodies Underlies Monocyte Activation in Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2015, 126, 2244-2244.	1.4	1
43	Atherosclerosis is not a risk factor for antiplatelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1191-1193.	3.4	1
44	T2 Magnetic Resonance: A Diagnostic Platform for Studying Integrated Hemostasis in Whole Blood—Proof of Concept. <i>Clinical Chemistry</i> , 2014, 60, 1174-1182.	3.2	26
45	Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. <i>Blood</i> , 2014, 123, 1596-1603.	1.4	311
46	Atomic Level Description of the Immune Complex That Causes Heparin-Induced Thrombocytopenia (HIT). <i>Blood</i> , 2014, 124, 465-465.	1.4	0
47	Fc γ RIIA Mediates the Prothrombotic Role of Monocytes in HIT. <i>Blood</i> , 2014, 124, 575-575.	1.4	0
48	Anti-Apoptotic Effects of Platelet Factor 4 on Human T-Lymphocytes. <i>Blood</i> , 2014, 124, 1418-1418.	1.4	0
49	New Insights into the Prothrombotic State of Heparin-Induced Thrombocytopenia (HIT) Using a Novel Microfluidic System: The Endothelial Lining and "Rolling Barrage" of Activation. <i>Blood</i> , 2014, 124, 574-574.	1.4	0
50	Understanding the Underlying Immune Response in HIT: Uptake of PF4/Heparin Complexes By Monocytes & Dendritic Cells. <i>Blood</i> , 2014, 124, 4197-4197.	1.4	0
51	Distinct Specificity and Single-molecule Kinetics Characterize the Interaction of Pathogenic and Non-pathogenic Antibodies against Platelet Factor 4-Heparin Complexes with Platelet Factor 4. <i>Journal of Biological Chemistry</i> , 2013, 288, 33060-33070.	3.4	24
52	Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. <i>Blood</i> , 2013, 121, 1858-1867.	1.4	84
53	Imaging Morphologic Changes On Platelet and Monocyte Surfaces In Heparin-Induced Thrombocytopenia (HIT). <i>Blood</i> , 2013, 122, 3533-3533.	1.4	8
54	Role Of Monocyte Fc γ Receptors In The Prothrombotic State Of Heparin Induced Thrombocytopenia (HIT). <i>Blood</i> , 2013, 122, 570-570.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Polyhedrocytes: Compressed Polyhedral Erythrocytes In Contracted Blood Clots and Thrombi. <i>Blood</i> , 2013, 122, 452-452.	1.4	1
56	â€œRadicalâ€•model of thrombosis. <i>Blood</i> , 2012, 119, 1798-1799.	1.4	3
57	Dynamic antibody-binding properties in the pathogenesis of HIT. <i>Blood</i> , 2012, 120, 1137-1142.	1.4	65
58	Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces. <i>Biomaterials</i> , 2012, 33, 5803-5811.	11.4	50
59	Miniaturized T2MR Magnetic Resonance System for Analysis of Hemostasis and Detection of Impaired and Prothrombotic Blood Disorders. <i>Blood</i> , 2012, 120, 1118-1118.	1.4	6
60	Fibrin Generation in Heparin-Induced Thrombocytopenia (HIT): Pathomechanistic Background for Novel Therapy and Prophylaxis. <i>Blood</i> , 2012, 120, 635-635.	1.4	2
61	The Two Phases of Heparin-Induced Thrombocytopenia (HIT): Early Monocyte/Tissue Factor (TF) Phase and Late Platelet Phase. <i>Blood</i> , 2012, 120, 270-270.	1.4	1
62	Platelet-Targeted, Thrombin-Activatable Fibrinolytic Pro-Drugs As Novel Therapies: Application to the Prothrombotic Disorder of Heparin-Induced Thrombocytopenia (HIT). <i>Blood</i> , 2012, 120, 1171-1171.	1.4	0
63	Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. <i>Blood</i> , 2011, 118, 2882-2888.	1.4	30
64	Microfluidic and Flow Cytometric Studies Support a Role for Monocytes and Coated Platelets in the Prothrombotic State in Heparin-Induced Thrombocytopenia (HIT). <i>Blood</i> , 2011, 118, 539-539.	1.4	1
65	â€œRolling Recruitmentâ€•of Endothelial Cell (EC) Activation in the Prothrombotic Nature of Heparin-Induced Thrombocytopenia (HIT). <i>Blood</i> , 2011, 118, 536-536.	1.4	0
66	FcÎ³RIIa Enhances Thrombus Growth in Vitro and in Vivo. <i>Blood</i> , 2011, 118, 191-191.	1.4	0
67	Formation of Procoagulant Platelets in Heparin-Induced Thrombocytopenia (HIT) Follows a Unique Signaling Pathway. <i>Blood</i> , 2011, 118, 197-197.	1.4	0
68	Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. <i>Blood</i> , 2010, 116, 5021-5031.	1.4	134
69	Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. <i>Thrombosis Research</i> , 2010, 125, 292-296.	1.7	139
70	Infusion of mature megakaryocytes into mice yields functional platelets. <i>Journal of Clinical Investigation</i> , 2010, 120, 3917-3922.	8.2	106
71	Heparin-Induced Thrombocytopenia Antibodies Inhibit PF4-Dependent Enhancement of Activated Protein C Formation by Binding to Antigenic Complexes Formed with the Chondroitin Sulfate Side-Chain of Thrombomodulin. <i>Blood</i> , 2010, 116, 721-721.	1.4	0
72	Platelet Factor 4 Levels Inversely Correlate with Platelet Transfusion Needs In Pediatric Patients Treated for Standard Risk Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 725-725.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Visualizing the Molecular and Cellular Basis of Heparin Induced Thrombocytopenia.. Blood, 2009, 114, 228-228.	1.4	0
74	Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood, 2008, 111, 3458-3467.	1.4	59
75	Monocytes Are a Particularly Favorable Target for Surface Platelet Factor 4 (PF4) Antigenic Complex Formation in Heparin-Induced Thrombocytopenia: New Insights into the Thrombotic Risk in HIT. Blood, 2008, 112, 271-271.	1.4	1
76	Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood, 2007, 110, 1153-1160.	1.4	107
77	Heparin-induced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. Journal of Clinical Apheresis, 2007, 22, 31-36.	1.3	74
78	Characterizing Factor VIII Inhibitor Resistance of Platelet-Delivered Factor VIII in the Treatment of Hemophilia A.. Blood, 2007, 110, 781-781.	1.4	2
79	Defining the Role of Monocytes in Heparin-Induced Thrombocytopenia (HIT): Insights from a Murine HIT Model.. Blood, 2007, 110, 280-280.	1.4	2
80	Surface Heparinization of Polyurethane Via Bromoalkylation of Hard Segment Nitrogens. Biomacromolecules, 2006, 7, 317-322.	5.4	41
81	Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood, 2006, 107, 2346-2353.	1.4	234
82	Murine In Vivo Studies Support Platelet Factor 4 as a Negative Autocrine of Megakaryopoiesis with Clinical and Therapeutic Implications.. Blood, 2006, 108, 93-93.	1.4	1
83	Release of High Levels of Platelet Factor 4 (PF4) from Platelets Improves Survival after a Lethal Lipopolysaccharide (LPS) Challenge.. Blood, 2006, 108, 61-61.	1.4	0
84	Platelet Factor 4 (PF4) Antigenic Complexes on the Macrophage Surface: Implications for the Pathogenesis of Heparin Induced Thrombocytopenia (HIT).. Blood, 2006, 108, 94-94.	1.4	0
85	Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood, 2005, 105, 131-138.	1.4	272
86	Pathogenic Role of Surface Platelet Factor 4 Complexes in Heparin-Induced Thrombocytopenia: Diagnostic and Therapeutic Implications.. Blood, 2005, 106, 55-55.	1.4	1
87	A Human Antibody, Cloned from a Patient with Heparin-Induced Thrombocytopenia, That Binds Heparin/Platelet Factor 4 Complexes.. Blood, 2005, 106, 58-58.	1.4	0
88	Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood, 2004, 104, 3173-3180.	1.4	140
89	Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. International Immunology, 2002, 14, 1303-1311.	4.0	85
90	Induction of Biologically Active Antineutrophil Cytoplasmic Antibodies by Immunization with Human Apoptotic Polymorphonuclear Leukocytes. Clinical Immunology, 2002, 103, 69-78.	3.2	29

#	ARTICLE	IF	CITATIONS
91	Adverse Effects of Intravenous Immunoglobulin Therapy in 56 Patients with Autoimmune Diseases. <i>Pharmacology</i> , 2001, 62, 133-137.	2.2	103
92	Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins. <i>Seminars in Immunopathology</i> , 2001, 23, 447-457.	4.0	7
93	Intravenous immunoglobulin treatment of lupus nephritis. <i>Seminars in Arthritis and Rheumatism</i> , 2000, 29, 321-327.	3.4	96
94	Immunization of Low-density Lipoprotein Receptor Deficient (LDL-RD) Mice with Heat Shock Protein 65 (HSP-65) Promotes Early Atherosclerosis. <i>Journal of Autoimmunity</i> , 2000, 14, 115-121.	6.5	125